Status:
COMPLETED
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
Lead Sponsor:
Arpida AG
Conditions:
Skin Diseases, Bacterial
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The study is now completed
Detailed Description
Primary Objective: The primary objective of this study is to compare the clinical cure rates of iclaprim and linezolid at the test of cure (TOC) visit (7 to 14 days after the end of treatment). Seco...
Eligibility Criteria
Inclusion
- Diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen.
Exclusion
- Known or suspected hypersensitivity to any study medication or other related anti-infective medication
- Any known or suspected condition or concurrent treatment contraindicated by the prescribing information
- Previous enrollment in this study
- Treatment with any investigational drug within 30 days before enrollment
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00303550
Start Date
March 1 2006
Last Update
March 27 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Edward Hospital & Health Services
Naperville, Illinois, United States, 60540
2
Wyoming Medical Center
Casper, Wyoming, United States, 82601